1. Biomarker may identify neuroblastoma patients most likely to benefit from immunotherapy

    Biomarker may identify neuroblastoma patients most likely to benefit from immunotherapy

    Among patients with high-risk neuroblastoma, those who had a certain combination of genotypes gained substantial benefit from adding immunotherapy to isotretinoin treatment, while it is uncertain whether those who lacked the combination gained benefit...

    Read Full Article
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video

    1. We wanted to determine if certain genotypes that are related to immune cells called NK cells— KIR/KIR-ligand genotypes—could be predictive of how patients with high-risk neuroblastoma respond to immunotherapy.
    2. Our data show that a certain combination of KIR/KIR-ligand genotypes may be predictive of benefit from immunotherapy
    3. Our data not only identify KIR/KIR-ligand genotypes associated with differences in outcome following treatment with immunotherapy but also indicate that the immune cells that are regulated by KIR/KIR-ligand interactions, namely NK cells, play a major role in mediating the anticancer effects of this immunotherapy treatment.
  3. Topics Mentioned